Applied Therapeutics (NASDAQ: APLT) details Q2 2025 earnings press release

Rhea-AI Filing Summary

Applied Therapeutics, Inc. filed a current report to disclose that it issued a press release announcing its financial results for the quarter ended June 30, 2025. The company furnished this press release as Exhibit 99.1 to the report, meaning it is provided for information purposes rather than being treated as filed under certain liability provisions of the Exchange Act. The report also notes that the cover page inline XBRL data is included as Exhibit 104, and it is signed by Les Funtleyder as Interim Chief Executive Officer and Chief Financial Officer.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0001697532false00016975322025-08-132025-08-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2025

APPLIED THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38898		81-3405262
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

545 Fifth Avenue, Suite 1400 New York, NY		10017
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (212) 220-9226

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock		APLT		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Item 2.02. Results of Operations and Financial Condition.

On August 13, 2025, Applied Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

The following exhibit is attached with this current report on Form 8-K:

Exhibit No.		Description
99.1		Press Release, dated August 13, 2025.
104		Cover Page Interactive Data File - the cover page iXBRL tags are embedded within the inline XBRL document.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	APPLIED THERAPEUTICS, INC.
Dated: August 13, 2025	By:	/s/ Les Funtleyder
	Name:	Les Funtleyder
	Title:	Interim Chief Executive Officer and Chief Financial Officer

FAQ

What did Applied Therapeutics (APLT) report in this 8-K filing?

Applied Therapeutics reported that it issued a press release announcing its financial results for the quarter ended June 30, 2025, which is furnished as Exhibit 99.1.

Which period do the reported financial results for Applied Therapeutics (APLT) cover?

The financial results announced by Applied Therapeutics cover the quarter ended June 30, 2025.

Where can investors find the detailed Q2 2025 results for Applied Therapeutics (APLT)?

The detailed results are contained in the press release that is furnished as Exhibit 99.1 to the report.

How is the Applied Therapeutics (APLT) press release treated under SEC rules?

The press release and the information in Item 2.02 are furnished, not filed, so they are not subject to Section 18 liability of the Exchange Act unless specifically incorporated by reference elsewhere.

Who signed this Applied Therapeutics (APLT) 8-K report?

The report was signed on behalf of Applied Therapeutics by Les Funtleyder, Interim Chief Executive Officer and Chief Financial Officer.

On which exchange is Applied Therapeutics (APLT) common stock listed?

Applied Therapeutics common stock is listed on The Nasdaq Global Market under the trading symbol APLT.